Urologic Oncology: Seminars and Original Investigations
Review articlePotential use of circulating endothelial cells as a biomarker of renal cell carcinoma
Introduction
Renal cell carcinoma (RCC) represents approximately 3% of all cancers worldwide [1]. In 2008, an estimated 46,232 diagnoses were made in the United States alone, of which approximately 11,059 resulted in death [2]. The majority are now detected through abdominal ultrasounds or CT scans, often incidentally while evaluating nonspecific symptoms [1]. Consequently, many renal tumors are now detected earlier in the course of disease, presenting smaller and at a lower stage and grade. Nevertheless, up to 30% of patients with RCC have metastatic disease at presentation, and recurrence develops in 40% of patients treated for localized disease [3], thus requiring some form of systemic therapy.
Section snippets
The challenge: Prognosis, not diagnosis
With the advent of superior imaging techniques for diagnosis, the need for more accurate prognostication has intensified. The clinical management of RCC involves a series of critical decisions that are strongly influenced by the patient's prognosis, which ultimately dictates the treatment options. For patients with metastatic disease, in addition to prognostication, there is a need to accurately determine the optimal biologic dose of anti-angiogenic agents, as well as a method to monitor
Tumor vascularization
Given that a biomarker for RCC does not exist, the question that follows is: From where and how should this biomarker be derived? Quite possibly, the answer may lie with tumor neovascularization. In terms of cancer etiology, vascularization is considered one of the six established hallmarks of solid, malignant tumors [12]. Small tumors can acquire sufficient nutrients and oxygen through simple diffusion, but this becomes inefficient once cells are located further than 100 to 200 μm from a blood
Tumor vascularization in RCC: Molecular mechanism
The rationale for a surrogate marker of angiogenesis as a biomarker of RCC progression is straightforward—renal cell carcinoma is inherently a highly vascular tumor [21], [22], [23], [24], with the relationship clearly that the larger the tumor, the greater the network of blood vessels required.
The link between angiogenesis and RCC is further highlighted by the genetics of RCC tumorigenesis [25], [26], [27]. In the autosomal dominant von Hippel-Lindau (VHL) syndrome, patients develop hundreds
Tumor vascularization in RCC: Clinical evidence from antiangiogenic therapy
The introduction of antiangiogenic treatment as systemic therapy for metastatic RCC further underlines the crucial role of vascularization in RCC progression. In more aggressive cases, traditional cytotoxic chemotherapy has yielded poor results, with response rates typically less than 15% [28], [29], [30], [31], [32]. Subsequently interferon-α and interleukin-2 therapy have yielded relatively low response rates and toxic side effects, encouraging the continual search for alternative agents for
Tumor vascularization: Predictor of patient outcomes in RCC
Given the body of evidence demonstrating the integral role of vascularization in RCC progression, it is logical to consider this as a possible marker of disease outcome. Previous studies have compared microvessel density (MVD), a common measure of tumor vascularity, with patient survival in RCC. Determined by staining for surface antigens typically expressed on endothelial cells, MVD is now widely accepted as an indicator of disease severity across a range of cancers, including melanomas,
Endothelial cells: Potential biomarkers for RCC
While the true prognostic value of MVD and VEGF remains to be determined, recent attention has now focused on two populations of cells, CECs and CEPs, and their role as surrogate markers of tumor neovascularization. Whilst their utility in predicting RCC progression specifically is unclear, previous studies have already correlated their levels with tumor progression and progression-free survival across a range of malignancies. This review will now focus on these studies, building a rationale
Circulating endothelial cells
Circulating endothelial cells (CECs), a subpopulation of endothelial cells thought to originate from blood vessel walls, shed into the circulation following detachment from the basement membrane [49]. This sequence of events is integral to the angiogenic process that occurs in the body physiologically and in some pathologic contexts, such as in tumor growth. CECs express the phenotype of mature, terminally differentiated endothelial cells [49].
Bone marrow derived circulating endothelial progenitors (CEPs)
Circulating endothelial progenitors (CEPs) comprise a separate population of cells that originate from the bone marrow, expressing a pattern of surface antigens typically observed in stem cells [50]. CEPs are thought to play a role in the formation of new blood vessels through vasculogenesis [50].
Detection and identification of CECs and CEPs
CECs are traditionally considered to be CD31+CD45–. For greater specificity, CD146+ staining can be utilized as it is most typically expressed on endothelial cells. CEPs, on the other hand, are considered to be CD31+CD45intermediateCD133+. In reality however, CEPs are a collection of phenotypically heterogenous stem cells that are still highly influenced by their surrounding environment [51].
CECs as biomarkers of tumor progression
An elevation in CECs has been observed in various diseased states ranging from vasculitis, kidney transplant rejection to myocardial infarction [52]. This observation extended to cancer patients, where Mancuso et al. measured higher levels of CECs in patients across a range of malignancies compared to healthy controls [53]. Interestingly, CEC levels were found to decrease in response to treatment, observed in patients post-chemotherapy for lymphoma, and post-mastectomy for breast cancer.
Some of
CEP contribution to tumor vascularization
The correlation between CEP levels and tumor progression has also been investigated across several malignancies, although this remains to be examined in the RCC context. Results have indicated that CEPs contribute to tumor vasculature in Lewis lung carcinoma [56], neuroblastomas [19], mammary adenocarcinomas [57], and lymphomas [58]. These results were supported by Peters et al., who utilized fluorescent in situ hybridization (FISH) techniques to demonstrate that up to 12.1% of tumor
Conclusions
The literature presented thus far highlights the ongoing need for improved disease-specific markers for RCC to better characterize patient prognosis and monitor disease recurrence. As surrogate markers of neovascularization, CECs and CEPs, show potential to reflect the progression of tumor growth. This relationship has been examined through animal models and clinical studies, although CECs and CEPs have not yet been examined specifically in an RCC setting. Nevertheless, the intrinsically high
References (71)
- et al.
Renal Cell Carcinoma Guideline
Eur Urol
(2007) - et al.
Prognostic factors for renal cell carcinoma
Cancer Treatment Rev
(2008) - et al.
The hallmarks of cancer
Cell
(2000) - et al.
Microvessel density in renal cell carcinoma—lack of prognostic significance
Urology
(1995) - et al.
Chemotherapeutic strategies for renal cell carcinoma
Urol Clin North Am
(2003) - et al.
Cytotoxic chemotherapy for advanced renal cell carcinoma
Urol Clin North Am
(1993) - et al.
Clinical significance of tumor angiogenesis in patients with localized renal cell carcinoma
Urology
(1998) - et al.
Vascular endothelial growth factor as prognostic factor in renal cell carcinoma
J Urol
(2000) - et al.
Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumor stage and vascularization in renal cell carcinoma
Eur J Cancer
(1999) - et al.
Serum angiogenic activity: Diagnostic relevance in renal cell carcinoma
Eur Urol
(2002)
Lymphangiogenesis and angiogenesis in conventional renal cell carcinoma: Association with vascular endothelial growth factors A to D immunohistochemistry
Urology
Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib
Ann Oncol
Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients
Ann Oncol
Resting and activated endothelial cells are increased in the peripheral blood of cancer patients
Blood
Genetically tagging endothelial cells in vivo: Bone marrow-derived cells do not contribute to tumor endothelium
Blood
Bevacizumab plus interferon-α-2a for treatment of metastatic renal cell carcinoma: A randomized, double-blind phase III trial
Lancet
Cancer Facts and Figures 2008
Systemic therapy for metastatic renal cell carcinoma
Urol Clin North Am
Surrogate end points in clinical trials: Are we being misled?
Ann Intern Med
Use of the University of California Los Angeles Integrated Staging System to Predict Survival in Renal Cell Carcinoma: An International multicenter study
J Clin Oncol
Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma
J Clin Oncol
Evidence of efficacy: Researchers investigating markers for angiogenesis inhibitors
J Natl Cancer Inst
Pathological and clinical findings to predict tumor extent of nonpalpable (stage T1C) prostate cancer
JAMA
New tumor markers: CA125 and beyond
Int J Gynecol Cancer
International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers
J Clin Oncol
Angiogenesis in cancer and other diseases
Nature
What is the evidence that tumors are angiogenesis dependent?
J Natl Cancer Inst
Tumorigenesis and the angiogenic switch
Nat Rev Cancer
Mechanisms of angiogenesis
Nature
Vasculogenesis
Annu Rev Cell Dev Biol
Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization
Circ Res
Bone marrow-derived cells contribute to tumor neovasculature and when modified to express an angiogenesis inhibitor can restrict tumor growth in mice
Clin Cancer Res
Tumor response to radiotherapy regulated by endothelial cell apoptosis
Science
Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organ-specific metastasis of renal cell carcinoma
Cancer
Dynamic CT evaluation of tumor vascularity in renal cell carcinoma
Am J Roentgenol
Cited by (4)
Quantification of peripheral blood CD133 mRNA in identifying metastasis and in predicting recurrence of patients with clear cell renal cell carcinoma
2014, Urologic Oncology: Seminars and Original InvestigationsCitation Excerpt :A wide variety of molecular markers, including mediators of cellular proliferation, the hypoxia-inducible pathway, cell cycle regulators, and adhesion molecules, have been demonstrated to be the powerful marker for the diagnosis or prognosis of RCC [17–19]. Many studies also indicate that progenitor cells play a role of cancer progression: initiation of metastasis and disease progression [20–22]. Recently, vascular endothelial growth factor receptor 1 (VEGFR1)–positive hematopoietic progenitor cells have also been linked to the regulation of metastasis [23].
Detection of circulating tumor cells and their potential use as a biomarker for advanced renal cell carcinoma
2019, Canadian Urological Association JournalResearch advancement in lymphangiogenesis in renal cell carcinoma
2013, Chinese Journal of Clinical Oncology